Introduction
============

The Hedgehog (HH)--GLI signaling is a conserved developmental pathway whose physiological roles in mammals consist of organogenesis, stem cell maintenance, and the upkeep and repair of adult tissues.^[@bib1]^ Core pathway components include the secreted signaling proteins---Sonic HH (SHH), Indian HH or Desert HH---which bind to and inactivate the transmembrane receptor Patched (PTCH) on nearby target cells, annulling its repression of a second transmembrane receptor, Smoothened (SMO). The complex downstream signaling culminates in the expression of glioma-associated oncogene (GLI)-family transcription factors (GLI1, GLI2 and GLI3), whose targets comprise context-specific genes that regulate differentiation, proliferation and survival. GLI proteins also regulate the expression of genes encoding several HH pathway components, including *GLI1* itself and *PTCH1*,^[@bib2]^ thereby creating positive and negative feedback loops.

Aberrant activation of the HH--GLI cascade can be caused by a number of factors, including genetic alteration(s) involving individual pathway components (for example, mutations affecting *PTCH* or *SMO*,^[@bib3]^ GLI1/2 amplification^[@bib4],\ [@bib5]^), and this anomalous signaling activity has been implicated in the initiation, progression and relapse of various types of cancer. In several epithelial forms of cancer, the tumor cells are reportedly dependent on autocrine HH--GLI stimulation.^[@bib6]^ In other studies, however, HH-expressing neoplastic epithelial cells appear to be unresponsive to the ligand they produce, which acts instead on cells in the tumor stroma to create a microenvironment favorable for tumor growth.^[@bib6]^ Inappropriate HH--GLI signaling also plays critical roles in maintaining the undifferentiated, self-renewing phenotype of the cancer stem cell (CSC) populations in hematological malignancies and solid tumors (including those of the lung, breast, pancreas, colon and brain).^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11]^ These tumor-initiating subpopulations are considered major drivers of tumor maintenance, metastasis, relapse and resistance to chemotherapy.^[@bib12],\ [@bib13]^ The HH--GLI pathway is thus an intriguing potential target for novel therapies for these cancers.

Several small-molecule inhibitors have been developed that suppress HH--GLI signaling via SMO blockade. Encouraging clinical results have been achieved in patients with medulloblastoma or basal cell carcinoma, which are associated with canonical HH--GLI signaling activation.^[@bib14]^ In contrast, treatment of colorectal, gastric and ovarian cancers with these agents has not produced any significant responses.^[@bib14]^ HH--GLI signaling is also known to play crucial cell-intrinsic roles in the development and maintenance of small-cell lung cancer.^[@bib15]^ However, in patients with newly diagnosed extensive-stage small-cell lung cancer, the addition of SMO inhibition to standard chemotherapy regimens does not appear to offer any benefit in terms of progression-free or overall survival.^[@bib16]^

Similar pictures are emerging of non-small-cell lung cancers (NSCLC), which account for approximately 85% of lung malignancies.^[@bib17]^ Several lines of evidence suggest that HH--GLI signaling is a major player in NSCLC tumorigenesis and maintenance. The two main NSCLC histotypes, adenocarcinomas (LACs) and squamous cell carcinomas (LSCCs),^[@bib18]^ express the GLI1 transcription activator^[@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^ as well as the HH ligand SHH.^[@bib23]^ In both histotypes, overexpression of HH--GLI pathway components has been linked to more aggressive behavior.^[@bib21],\ [@bib22],\ [@bib24]^ Clinical trials are underway on the use of SMO inhibitors in advanced solid tumors including NSCLCs, but recently published preclinical data indicate that these agents are likely to exert few if any antitumoral effects on LSCC or LAC cells.^[@bib24],\ [@bib25]^ Importantly, however, LSCC cell lines that were unaffected by shRNA-mediated depletion of SMO or its pharmacological inhibition responded to genetic and pharmacological targeting of GLI with significant decreases in growth and markedly increased apoptosis.^[@bib24]^ These findings are consistent with the noncanonical, SMO-independent activation of GLI-mediated transcription by input from other signaling pathways^[@bib26],\ [@bib27]^ such as the neuropilin-2/ERK (NRP2/ERK) cascade,^[@bib28]^ K-Ras/ERK signaling^[@bib29]^ and the mTOR/S6K1 pathway.^[@bib30]^ These considerations induced us to take a closer look at the molecular mechanisms underlying HH--GLI pathway activation in LACs and the role played by this pathway in LAC CSCs.

Results
=======

Expression of HH--GLI signaling pathway components in NSCLC
-----------------------------------------------------------

Interrogation of Oncomine^[@bib31]^ microarray data sets on 1007 NSCLC tissues revealed positive correlation between *GLI1* and *SMO* mRNA levels only in the LSCCs ([Supplementary Figure S1a](#sup1){ref-type="supplementary-material"}). Consistently, immunohistochemistry (IHC) analyses of human NSCLC tissue arrays disclosed GLI1 protein expression in most LACs (76%) and LSCCs (60%), but over half the GLI1-positive LACs exhibited weak SMO staining ([Figures 1a and b](#fig1){ref-type="fig"}). SHH was expressed in 28% of the LSCCs and 35% of the LACs ([Supplementary Figure S1b](#sup1){ref-type="supplementary-material"}).

GLI1 and SMO expression were then assessed in commercial cell lines and patient-derived CSC lines derived from NSCLCs (see [Supplementary Table S1](#sup1){ref-type="supplementary-material"} for genotypes).^[@bib32],\ [@bib33]^ GLI1 was expressed in all cell lines. SMO expression varied and was particularly low in three LAC cell lines tested (H1437, CSC-3 and CSC-4---referred to hereafter as \'SMO^low^ cells\'), as compared with both LSCC lines tested (H520 and CSC-1) and with the remaining three LAC lines (\'SMO^high^ cells\') ([Figures 1c and d](#fig1){ref-type="fig"}).

Aberrant methylation of the *SMO* promoter region in LAC
--------------------------------------------------------

Re-interrogation of the Oncomine^[@bib31]^ data sets revealed no NSCLC-associated deletions/mutations involving the *SMO* region (chromosome 7, band 7q32.1) that might explain the heterogeneous expression documented in the LAC cell lines. To explore the possibility that the low expression in H1437, CSC-3 and CSC-4 reflected epigenetic silencing of *SMO*, which has been described in colorectal cancer,^[@bib34],\ [@bib35]^ we interrogated the MethHC database.^[@bib36]^ Compared with patient-matched normal lung (NL) tissue, LACs (but not LSCCs) exhibited significantly higher *SMO* promoter methylation levels ([Supplementary Figure S1c](#sup1){ref-type="supplementary-material"}). Pyrosequencing was then used to quantify DNA methylation at 42 CpG dinucleotides in the *SMO*'s proximal regulatory region ([Supplementary Figures S1d and e](#sup1){ref-type="supplementary-material"}). Methylation levels in SMO^low^ LAC cells (\~50% for CSC-4 and H1437) were significantly higher than those observed in SMO^high^ cells (\~5 for CSC-2, \~30% for H1734) ([Figures 1e and f](#fig1){ref-type="fig"} and [Supplementary Figure S1e](#sup1){ref-type="supplementary-material"}). Treatment with the demethylating agent 5-azacytidine (5-AZA) was followed by significantly reduced methylation levels and increased *SMO* expression (mRNA and protein) in SMO^low^ cells, but it had no effect on SMO^high^ cells ([Figures 1g and h](#fig1){ref-type="fig"}).

Abrogation of SMO activity using shRNA-mediated knockdown (shSMO) or the SMO antagonist vismodegib^[@bib37]^ reduced GLI1 transcription and cell proliferation in SMO^high^ cells but had no effects in SMO^low^ cancer cells or in both SMO^high^ and SMO^low^ CSCs ([Supplementary Figures S2a--h](#sup1){ref-type="supplementary-material"}). The ineffectiveness of SMO inhibition in LAC CSCs is consistent with previous reports.^[@bib25]^

To investigate SMO function further, we treated LAC cancer cells with the SMO agonist purmorphamine.^[@bib38],\ [@bib39]^ As shown in [Supplementary Figures S2i and j](#sup1){ref-type="supplementary-material"}, purmorphamine produced increases in GLI1 expression and cell viability in SMO^high^ cells but its effects in SMO^low^ cells were not significant. When cells were pretreated with 5-AZA, however, the effects of purmorphamine on GLI1 levels and cell viability were significant in the SMO^low^ cancer cells ([Supplementary Figures S2i and j](#sup1){ref-type="supplementary-material"}). These results indicate that *SMO* expression may be epigenetically silenced in LAC cells, that in LAC CSCs regardless of SMO levels, SMO inhibition is ineffective and that in LAC cancer cells SMO retained mild functionality.

GLI1 inhibition reduces LAC cell survival and CSC stemness features
-------------------------------------------------------------------

Direct targeting of GLI1 activity had more substantial effects in LAC cell lines and CSCs. Silencing of GLI1 significantly reduced viability in all lines tested ([Figures 2a and b](#fig2){ref-type="fig"}), and similar results were achieved when the cells were treated with GANT61, whose direct binding to GLI1 and GLI2 inhibits the latters' DNA binding and their transcriptional output.^[@bib40],\ [@bib41]^ GANT61 is known to target GLI1 specifically,^[@bib42]^ and numerous groups have demonstrated its high efficacy against human cancer cells (reviewed in Gonnissen *et al.*^[@bib41]^). As shown in [Figures 2c and d](#fig2){ref-type="fig"}, GANT61 treatment significantly downregulated GLI1 levels in all LAC cell lines, regardless of their SMO expression status, and this inhibition was associated with significantly diminished cell viability and enhanced apoptosis ([Supplementary Figure S3a](#sup1){ref-type="supplementary-material"}).

Abrogation of GLI1 activity with shGLI1 or GANT61 treatment also diminished the self-renewal capacity of LAC CSCs, as reflected by their ability to form oncospheres ([Figure 2e](#fig2){ref-type="fig"}). Interestingly, when sh*GLI1*-transduced CSCs were treated with GANT61, no additional decline was observed in the frequency of oncosphere-forming cells (OFCs), which suggests that the drug's effects in LAC CSCs are mediated by its inhibition of GLI1. GANT61 treatment also significantly reduced the number of CSCs exhibiting high aldehyde dehydrogenase activity ([Figure 2f](#fig2){ref-type="fig"}), which is an established marker of lung CSCs.^[@bib43],\ [@bib44]^ The drug also reduced the expression of the lung CSC marker OCT4 ([Figure 2g](#fig2){ref-type="fig"}),^[@bib32],\ [@bib45],\ [@bib46]^ and of the ATP binding cassette transporter ABCG2 ([Figure 2g](#fig2){ref-type="fig"}), which is commonly expressed by CSCs^[@bib47],\ [@bib48]^ and interestingly enough is reportedly regulated by HH pathway signaling.^[@bib49],\ [@bib50],\ [@bib51]^

GLI1 inhibition reduces growth of LAC CSC-derived xenograft tumors, attenuates their stemness and induces apoptosis
-------------------------------------------------------------------------------------------------------------------

Having established that *in vitro* GLI1 inhibition with GANT61 reduces the stemness and survival capacity of LAC CSCs, we investigated the drug's *in vivo* effects on LAC CSC-derived xenograft tumors (XTs) ([Supplementary Figure S4a](#sup1){ref-type="supplementary-material"}). Tumors in GANT61-treated mice displayed significantly slower growth than their untreated counterparts ([Figure 3a](#fig3){ref-type="fig"}), together with decreased transcription of *GLI1* and *PTCH1* ([Figure 3b](#fig3){ref-type="fig"}), downregulated expression of OCT4 and ABCG2 ([Figure 3c](#fig3){ref-type="fig"} and [Supplementary Figure S4b](#sup1){ref-type="supplementary-material"}), attenuated cell proliferation ([Figure 3d](#fig3){ref-type="fig"}) and increased apoptosis ([Figure 3e](#fig3){ref-type="fig"}). As shown in [Supplementary Figures S4c--e](#sup1){ref-type="supplementary-material"}, the features of GANT61-treated XTs were replicated in XTs generated with LAC CSCs that had been stably infected with shGLI1. Compared with vector-infected controls, shGLI1 XTs exhibited slower growth ([Supplementary Figure S4c](#sup1){ref-type="supplementary-material"}), attenuated stemness ([Supplementary Figure S4d](#sup1){ref-type="supplementary-material"}) and decreased cell proliferation ([Supplementary Figure S4e](#sup1){ref-type="supplementary-material"}). These findings confirm that *in vivo* inhibition of GLI1 exerts antitumoral effects in LAC.

Noncanonical GLI1 activation in LAC
-----------------------------------

The results of the experiments described thus far indicate that a substantial proportion of LACs are characterized by SMO-independent, GLI-mediated transcription, a phenomenon previously documented in other cancers. GLI1 regulation has been attributed to RAS/MEK signaling in breast cancer,^[@bib28]^ melanoma^[@bib52]^ and pancreatic ductal adenocarcinoma, and in the latter tumors, GLI1 proved to be indispensable for KRAS-induced carcinogenesis.^[@bib53]^

Interestingly, in breast cancer, HH--GLI signaling was triggered in an autocrine manner by stimulation of the VEGF receptor neuropilin-2 (NRP2),^[@bib28]^ whose expression in NSCLCs has been linked to unfavorable outcomes.^[@bib54],\ [@bib55],\ [@bib56]^ In its role as a VEGF receptor, NRP2 specifically binds both VEGFA and VEGFC,^[@bib57]^ and VEGF/NRP signaling impacts the biology of stem-like tumor cells in various types of cancer.^[@bib58],\ [@bib59],\ [@bib60]^ We wondered whether oncogenic NRP2/ERK signaling might be the upstream cause of the noncanonical GLI1 activity in LAC cells.

In support of this hypothesis, direct inhibition of MEK--ERK cascade in these cells with U0126^[@bib61]^ significantly reduced the levels of GLI1 and inhibited the phosphorylation of the MEK substrate ERK ([Figures 4a and b](#fig4){ref-type="fig"}). To determine whether the MEK--ERK axis directly regulates Gli1 activity through its modification, we investigated GLI1 phosphorylation in LAC cells treated with the selective MEK1/2 inhibitor U0126. As reported in [Figure 4c](#fig4){ref-type="fig"}, MEK inhibition caused a reduction of phosphorylated GLI1, corresponding to the active form of the transcription factor.^[@bib30]^ Investigation of the subcellular localization of phosphorylated GLI1 in LAC cells showed positive nuclear staining for GLI1, which shifted to the cytoplasm after U0126 treatment ([Figure 4d](#fig4){ref-type="fig"}). To study whether ERK1 directly phosphorylates GLI1, we performed an *in vitro* kinase assay using the purified recombinant fragment containing the predicted ERK-sensing N-terminal region of GLI1^[@bib62]^ and ERK1. As shown in [Figure 4e](#fig4){ref-type="fig"}, the results revealed direct phosphorylation of GLI1, adding further support to the conclusion that MEK1--ERK1/2 activates GLI1 transcriptional activity in LAC cells.

Experiments designed to elucidate the upstream role of NRP2 in the NRP2/ERK signaling showed that GLI1 expression was also significantly reduced in LAC cell lines after siRNA-mediated knockdown of NRP2 ([Figure 5a](#fig5){ref-type="fig"}). Similar decreases were seen in LAC CSCs following shRNA NRP2 knockdown ([Figure 5b](#fig5){ref-type="fig"}). Of note, NRP2 silencing was less effective in diminishing GLI1 expression in CSC-2, which harbor the oncogenic KRAS~G12C~ mutation ([Supplementary Table S1](#sup1){ref-type="supplementary-material"} and [Figures 5a and b](#fig5){ref-type="fig"}).

As shown in [Figure 5c](#fig5){ref-type="fig"}, si*NRP2* or si*GLI1* in LAC cells both produced significant decreases in viability. In line with NRP2's putative role as an upstream activator of GLI1 in these cells, we did not observe an additive effect when we combined *NRP2* and *GLI1* silencing.

To further clarify the role of KRAS mutation, we compared cell viability in CSC-2 (KRAS~G12C~ mut) and CSC-4 (KRAS~wt~). GLI1 knockdown diminished the viability on both CSC lines, whereas shNRP2 decreased it only on CSC-4 ([Figure 5d](#fig5){ref-type="fig"}). No additive effects were achieved with combined shNRP2 and shGLI1 depletion.

U0126-mediated inhibition of the MAPK/ERK/GLI1 signaling also diminished the viability of LAC cell lines and CSCs. Similar effects were achieved with direct targeting of GLI1 with GANT61, and no additive effects were observed after their combination ([Figures 5e and f](#fig5){ref-type="fig"}).

Finally, as shown in [Supplementary Figure S5a](#sup1){ref-type="supplementary-material"}, the GLI1-modulating role of the NRP2/ERK axis was confirmed by the significant upregulation in cells stimulated with recombinant VEGF. Consistent with previous reports indicating that NRP2 and VEGFA may be direct targets of GLI1,^[@bib28]^ transcript levels of both the receptor and its ligand in CSC-2 cells decreased significantly after siRNA-mediated GLI1 silencing ([Supplementary Figure S5b](#sup1){ref-type="supplementary-material"}).

Collectively, these findings support the existence of a self-amplifying autocrine signaling loop in LAC cells where VEGF/NRP2/MAPK/ERK signaling upregulates expression of GLI1 and GLI1 in turn enhances the expression and function of NRP2 and VEGF.

Our next set of experiments sought to document the existence of autocrine VEGF/NRP2/GLI1 signaling *in vivo* in LACs. Samples of LAC CSC-derived XTs were analyzed with quantitative PCR using assays specific for human transcripts to specifically characterize pathway component expression patterns in the cancer-cell compartments of tumors. Here we found *NRP2* and *VEGFA* transcripts levels that significantly exceeded those found in normal human lung tissue (NL) ([Figures 6a and b](#fig6){ref-type="fig"}). VEGFA was previously shown to be often overexpressed in NSCLC.^[@bib63]^ VEGFC was expressed at very low levels so we did not investigate its role further. Consistent with *in vitro* findings, XTs from GANT61-treated mice displayed significantly lower cancer-cell compartment levels of *NRP2* and *VEGFA* than those from control animals ([Supplementary Figure S6a](#sup1){ref-type="supplementary-material"}).

The existence of an autocrine loop indicated by our *in vitro* findings was supported by our *in vivo* data ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}).

Increasing evidence points to central roles for the tumor stroma in cancer maintenance.^[@bib64]^ In particular, *in situ* hybridization studies have demonstrated the presence in LAC stroma of HH pathway components.^[@bib19]^ In addition, exogenous SHH stimulation has been shown to activate canonical HH--GLI signaling in normal lung fibroblasts (LFs), upregulating their secretion of various oncogenic factors, including VEGF.^[@bib23]^ In all the XTs we analyzed, *SHH* mRNA was highly expressed in the cancer-cell compartments of the tumors ([Figures 6c and d](#fig6){ref-type="fig"}), but it was undetectable in normal human lung (NL) and also in the XT stroma. As shown in [Figure 6e](#fig6){ref-type="fig"}, exposure of murine LFs to recombinant Shh markedly upregulated the transcription of *Gli1* as well as that of *VegfA*. Analysis of the stromal compartment of the LAC XTs revealed transcription of *Smo* (at levels resembling those in normal murine lung and skin fibroblasts (LF, SF) ([Supplementary Figure S6b](#sup1){ref-type="supplementary-material"}), *Gli1* (at levels significantly higher than those found in the normal fibroblasts) ([Figure 6f](#fig6){ref-type="fig"}) and *VegfA* ([Figure 6g](#fig6){ref-type="fig"}), and expression of the latter two genes was significantly downregulated in the stroma from GANT61-treated mice. These data suggest a paracrine SHH-mediated cross talk between the epithelial and stromal compartments of the tumor,^[@bib27]^ which activates canonical HH--GLI signaling in the stroma, thereby upregulating the expression of VEGFA ligand available for interaction with epithelial-cell NRP2.

Collectively, the above findings point to the existence in LACs of a complex network in which GLI1 signaling can be activated by autocrine stimulation, genetic alterations (for example, activating KRAS mutations) and cross talk between the epithelial and stromal compartments of the tumor ([Figure 7](#fig7){ref-type="fig"}).

Discussion
==========

LAC, the world's leading cause of cancer-related death, is characterized by high rates of somatic mutation and genomic rearrangement.^[@bib65]^ The most common genetic alteration involves *KRAS* (33%). Aberrant signaling through several oncogenic pathways has also been described in LACs: that is, mitogen-activated protein kinases (MAPK) activation (76%); phosphatidylinositol 3-kinases (PI3K)--AKT--mammalian target of rapamycin (mTOR) activation (25%) and TP53 alteration (63%).^[@bib65],\ [@bib66]^

Aberrant HH--GLI signaling has been implicated in the maintenance of various epithelial cancers, including those of lung.^[@bib14],\ [@bib19],\ [@bib39]^ In clinical trials, however, SMO inhibitors are producing disappointing results in several tumors.^[@bib14],\ [@bib16]^ Recently it has been shown that OFCs from LACs---unlike those from LSCCs---are unresponsive to drug-mediated SMO inhibition and authors concluded that these cells are probably not dependent on HH--GLI signaling.^[@bib25]^ The LAC CSC we studied were also unaffected by SMO inhibition, but our data indicate that their refractoriness is not a reflection of HH--GLI signaling's limited importance in these cells' but rather of its noncanonical nature.

Our findings indicate that the canonical downstream effector of the HH pathway, GLI1, is expressed by approximately 75% of all LACs, but surprisingly, in roughly half of these GLI1-positive tumors, key upstream activator of this pathway, SMO, is expressed at low levels, at least in part owing to hypermethylation of its promoter. Even in SMO^low^ cells, however, we found evidence of GLI1-mediated transcription that was crucial for maintaining the growth and stemness features of LACs. Although virtually unaffected SMO targeting, this noncanonical HH--GLI signaling could be significantly impaired by GLI1 inhibition with antitumoral effects *in vitro* as well as *in vivo*.

As illustrated in [Figure 7](#fig7){ref-type="fig"}, our data show that noncanonical activation of GLI1 in LAC cells is at least partially the result of oncogenic signaling through the MAPK/ERK pathway, a phenomenon that has been described in other types of cancer.^[@bib28],\ [@bib29],\ [@bib52],\ [@bib53],\ [@bib67]^ One of the mechanisms underlying activation of the MAPK/ERK/GLI1 cascade in LAC cells involves autocrine VEGFA stimulation of NRP2 receptors expressed by epithelial tumor cells. Autocrine VEGF/NRP2/GLI1 signaling has been implicated in the maintenance of tumor-initiating cells in breast cancer^[@bib28]^ and esophageal adenocarcinoma.^[@bib30]^ An autocrine loop involving NRP and VEGF has also been described in skin cancer, where the expression of VEGFA was shown to promote tumor growth not only by stimulating angiogenesis within the stroma but also by enhancing stemness features within the cancer-cell population.^[@bib58]^

MAPK/ERK/GLI1 signaling can also be upregulated by paracrine stimulation of the epithelial-cell NRP2 receptors by VEGFA secreted by the stroma. This form of epithelial-cell/stromal-cell cross talk is mediated by the expression and secretion of SHH by the epithelial cells of LACs, which activates *canonical* HH--GLI signaling in stromal cells, upregulating the transcription of *VEGFA* and other GLI1 target genes.^[@bib68],\ [@bib69],\ [@bib70]^ Our data build on and expands evidence of a potential role in lung cancer of HH--GLI signaling in the tumor stroma reported in earlier studies, where GLI1, SHH and PTCH transcripts were documented in LAC stromal cells.^[@bib19]^ Our data also extend observations by Bermudez *et al.*^[@bib23]^ that SHH secreted by lung cancer cells stimulates the proliferation of fibroblasts and their production of tumor-promoting factors, including VEGF.

Genetically determined, constitutive activation of KRAS is a well-known trigger of MAPK/ERK/GLI1 signaling.^[@bib29]^ However, KRAS mutation *per se* is not necessarily associated with oncogenic KRAS activity.^[@bib71]^ Functional comparison of various KRAS mutations in an *in vivo* system of vertebrate tumorigenesis showed tumorigenic effects for KRAS~G12C~ but not for KRAS~G13C~.^[@bib72]^ These results are in line with our finding that NRP2 silencing was less effective in reducing viability in LAC cells harboring the KRAS~G12C~ mutation than it was in KRAS~wt~ and KRAS~G13C~ cells.

*KRAS* mutation can also have important implications for paracrine stimulation of NRP2/GLI signaling in LAC epithelial cells. Mills *et al.*^[@bib53]^ have shown that SHH secreted by pancreatic cancer cells activates canonical HH--GLI signaling in stromal cells, mediated in part by the upregulated expression of another GLI1 target gene. Interestingly, the expression of SHH by the cancer cells was found to be regulated by KRAS. This mechanism could parallel the role of stroma-produced VEGF as a target of SHH induced GLI1 activation in stromal cells in our experiments.

Our results point to GLI1 as an important factor for maintaining the biological aggressiveness of LACs, which is fully in line with the results of a recent meta-analysis documenting the negative prognostic repercussions of GLI1 expression in a wide range of solid tumor types.^[@bib73]^ In our model, the tumor-promoting effects of GLI-mediated transcription are evident at multiple levels in LACs, including CSC and non-CSC components of the cancer-cell population and cells of the microenvironment that sustains them. Unlike approaches that target upstream regulators of GLI1 signaling, direct abrogation of GLI1 activity itself can exert antitumoral effects at all of these levels in LACs, *in vitro* and *in vivo.* GANT61 has been intensively used in various cancer research models; however, it has not been clinically tested.^[@bib41]^ Other GLI antagonists, such as arsenic trioxide^[@bib74]^ and atypical protein kinase C antagonists,^[@bib75]^ have been used in clinical settings, but both require further investigation since they have molecular targets other than GLI1. A more recently identified drug that specifically inhibits GLI1, glabrescione B,^[@bib76]^ is now undergoing preclinical investigation.

Prospective molecular profiling of LACs to assess their GLI1 status might be used to identify patients likely to benefit from GLI signaling blockade at different levels, with or without conventional chemotherapy or other promising biological approaches^[@bib77],\ [@bib78]^

Materials and methods
=====================

All commercial products were used according to suppliers' instructions unless otherwise indicated.

Gene expression data set analyses
---------------------------------

The Oncomine platform^[@bib31]^ was used to interrogate data sets for LACs (Broet Lung, Lee Lung and Weir Lung) and LSCCs (TCGA Lung, Bass Lung, Kuner Lung, Larsen Lung and Lee Lung). Probes belonging to the same category were pooled (700 samples for LACs, 347 for LSCCs). Pearson's *r* and correlation plots were generated to assess correlation between *SMO* and *GLI1* expression. The TCGA Lung 2 data set was interrogated for *SMO* mutations in NSCLCs.

The MethHC database^[@bib36]^ was interrogated to explore the methylation status of *SMO* CpG islands in NSCLC.

Cell cultures
-------------

### Cells

All cell lines were subjected to quality-control testing. NSCLC cell lines A549, H1437 and H1734 were purchased from the ATCC (Milan, Italy); H520 were provided by Prof. M Broggini. Patient-derived CSC lines were obtained from primary LSCC (CSC-1) or LAC (CSC-2, -3 and -4). CSC-1--3 lines were characterized in Eramo *et al.*^[@bib32]^ The CSC-4 line was isolated and characterized with internal review board approval at the University of Palermo. CSCs were maintained in advanced DMEM/F12 (Gibco Thermo Fisher Scientific, Waltham, MA, USA) supplemented with N2 (Gibco Thermo Fisher Scientific), B27 without vitamin A (Gibco Thermo Fisher Scientific), and 50 μg/ml insulin (Sigma-Aldrich, Milan, Italy), 20 ng/ml EGF and 10 ng/ml bFGF.

Murine lung and skin fibroblasts were isolated from NOD/SCID/IL2Rγnull mice as previously described.^[@bib79]^

### Treatments

Cells were treated (for 48 h unless otherwise specified) with the following: 10 μ[m]{.smallcaps} 5-AZA (Sigma-Aldrich); 20 μ[m]{.smallcaps} GANT61 (ENZO Lifesciences, Rome, Italy); 25 μ[m]{.smallcaps} vismodegib (Selleckchem, Rome, Italy); 15 μ[m]{.smallcaps} Purmorphamine (Selleckchem), 10 μ[m]{.smallcaps} U0126 (TocrisBioscience, Milan, Italy); 100 ng/ml Recombinant VEFG (R&D Systems, Minneapolis, MN, USA); 25 μg/ml anti-VEGF (R&D Systems); and 3 μg/ml recombinant SHH (R&D Systems). SiRNA-mediated silencing was performed with smart pool on-target plus GLI1 (ID: L-003896) and NRP2 (L-003896) (Dharmacon, Milan, Italy); non-target siRNA was used as a control. For shRNA-mediated knockdown, PLKO lentiviral particles carrying shRNA (Sigma-Aldrich): MISSION shRNA-non-target control Transduction Particles (SCH002V) and three Lenti shGLI1: MISSION shRNA Clone TRCN0000020485, TRCN0000020486 and TRCN0000020487. Three lenti shSMO were used: MISSION shRNA Clone TRCN0000378375, TRCN0000378354, TRCN0000358090; Clones TRCN0000020487 (shGLI1) and TRCN0000358090 (shSMO) demonstrated the best knockdown efficiency with less off target effect.

### Assays

To assess self-renewal, CSCs were plated at clonal density in 96-well plates. After 20 days the number of oncospheres was divided by the number of cells plated to determine the OFC frequency. Cell viability was assessed with MTS assay (Promega, Milan, Italy) and trypan blue exclusion. Aldehyde dehydrogenase activity was quantified with Aldefluor Kit (Stem Cell Technologies, Meda MB, Italy). All experiments were performed in at least three biological replicates.

Xenograft experiments
---------------------

XTs were generated as previously described.^[@bib32]^ CSCs (300 000 cells) were re-suspended in 100 μl of culture medium and Matrigel (1:1) (BD Pharmingen, Milan, Italy) and subcutaneously injected in the flanks of 6-week-old female NOD/SCID/IL2Rγnull mice (Charles River Laboratories, Calco, LC, Italy). Each experimental group consisted of six mice, allocated using a simple randomization method. Tumor volume (1/2(length × width^2^)) was assessed using digital caliper. Mice were treated with GANT61 (40 mg/kg, i.p.) re-suspended in ethanol and diluted to 100 μl per dose with 10% (2-hydroxypropyl)-β-cyclodextrin (vehicle) or vehicle alone (controls). Injections were administered twice a week for 4 weeks. All procedures were performed with the approval of the Ethics Committee for Animal Experimentation.

Immunohistochemistry
--------------------

Standard-protocol IHC was done on Human Lung Cancer Survey tissue microarrays (US Biomax, Milan, Italy) and formalin-fixed paraffin-embedded (FFPE) XT tissues. The UltraTek HRP Anti-Polyvalent (DAB) Staining System (ScyTek, Logan, UT, USA) was used for blocking and detection; apoptosis was detected with TUNEL-POD kit (Roche, Monza, Italy). Labeling was detected with the UltraTek HRP Anti-Polyvalent (DAB) Staining System (ScyTek). Stained sections were examined with a Leica DM1000 microscope (Leica Microsystems Srl, Milan, Italy), photographed with a Jenoptik ProgRes SpeedXT Core 3 camera (Jenoptik AG, Vienna, Austria), and analyzed with ProgRes Capture Pro 2.8 software (Jenoptik AG).

Protein expression was evaluated with histoscore method (*H*-score): staining intensity was rated from 0 (negative) to 3 (strong) for each sample by two independent observers and the mean was used. *H*-score was calculated multiplying the number of cells within each category in at least three different × 200 fields. Human protein KI-67 expression and TUNEL scores were reported as percentages of labeled cells with respect to total cells.

Analysis of CpG island methylation status
-----------------------------------------

DNA was extracted from LAC cells using Qiagen's QIAamp DNA Mini Kit. Methylation at the CpG islands in the *SMO* promoter was assessed by pyrosequencing, performed according to standard procedures by EpigenDx Inc. (<http://www.epigendx.com>).

Western blotting
----------------

Western blots were performed according to standard procedures.^[@bib80]^ Values are expressed as band integrals normalized to the strongest band and on the housekeeping gene.

Protein immunoprecipitation was performed as described in Canettieri *et al.*,^[@bib81]^ incubating 1.5 mg of each total protein extract with anti-Gli1 and mouse IgG (Santa Cruz Biotechnology, Heidelberg, Germany), as a negative control. Images were acquired using the BioRad ChemiDoc MP Imaging System (BioRad, Hercules, CA, USA).

*In vitro* kinase assay
-----------------------

Recombinant GST-GLI1N (fragment 2-234 AA) and GST were produced as described previously.^[@bib81]^ The *in vitro* kinase assay was performed as previously described.^[@bib82]^ Recombinant ERK1 was purchased from Sigma-Aldrich (E7407).

mRNA analysis
-------------

mRNA levels were analyzed as described in Po *et al.*^[@bib7]^ Endogenous controls were β-actin, GAPDH and HPRT for human samples, and Hprt1, β-2-microglobulin and GusB for murine. NL RNA was purchased from Thermo-Fisher Scientific (Waltham, MA, USA).

Immunofluorescence
------------------

Immunofluorescence was performed as described in Silvano *et al.*^[@bib83]^ Images were acquired with a Carl Zeiss microscope (Axio Observer Z1) and AxioVision Digital Image Processing Software (Zeiss, Jena, Germany).

Antibodies
----------

Santa Cruz Biotechnology: anti-SMO H-300 (sc-13943, IHC), anti-SMO N-19 (sc-6366, WB), anti-GLI1 H-300 (sc-20687, IHC), anti-actin I19 (sc-1616, WB), anti-NRP2 (sc-13117, IHC and WB), anti-p-ERK1/2 (sc-101761, WB) and anti-ABCG2 (sc-25821, WB). Abcam (Cambridge, UK): anti-SHH (ab53281, IHC), anti-GAPDH (ab8245, WB) anti-OCT4 (ab19857, WB and IHC) and Phospho---(Ser/Thr) (ab17464, WB-IP). Cell Signalling (Leiden, The Netherlands): anti-GLI1 (L42B10, WB). Thermo Fisher Scientific: Anti-KI-67 (RM-9106, IHC). EMD Millipore (Milan, Italy): Anti-human nuclei (MAB-1281, IHC) and anti-phospho-serine (\#16-455 Kinase assay).

Statistical analysis
--------------------

Results are expressed as means±s.d. from an appropriate number of experiments. Differences were analyzed by the Mann--Whitney *U*-test for non-parametric values with similar variance using the GraphPad Prism software Version 6.0 (La Jolla, CA, USA). Adjusted *P*-values of less than 0.05 were considered statistically significant.

We thank Alberto Gulino, friend, mentor and colleague, who passed away while the manuscript was in preparation, for his inspiring vision and continued support. This work was supported by Associazione Italiana Ricerca Cancro (AIRC and AIRC 5XMILLE), Ministry of University and Research (FIRB, PRIN and PON), Sapienza University of Rome (Ateneo), Pasteur Institute/Cenci Bolognetti Foundation, Umberto Di Mario ONLUS Foundation, Italian Institute of Technology (IIT) projects. Medical writing support was provided by ME Kent (EMWA) and funded by the Società Italiana Articoli Laboratorio S.r.l (Rome, Italy).

**Author contributions**

Conceptualization: EF, AP and CC; methodology: AP, MS and EM; investigation: AP, MS, EM, AE, VS, ZMB, MT, DC, GC, SC and LDiM; writing---original draft: AP, EF and EDeS; writing---review and editing: EF, IS and GC; funding acquisition: EF and EDeS and RDeM; resources: GS, MT and AE; supervision: EF.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on the Oncogene website (http://www.nature.com/onc)

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

![HH--GLI pathway components in NCSLC. (**a**, **b**) IHC of SMO and GLI1 protein expression in human NSCLC tissue arrays (216 LACs, 291 LSCCs): (**a**) distribution of SMO/GLI1 phenotypes and (**b**) representative images of GLI1 and SMO staining. The LSCC sample in (**b**) is positive (*H*-score \>50/300) for both proteins; the LAC displays only GLI1 positivity. Magnification × 20, inset × 40. Scale bar: 50 μm. (**c**, **d**) Western blots showing basal SMO and GLI1 protein expression in (**c**) commercial cell lines and (**d**) patient-derived CSCs from LSCC and LAC (see [Supplementary Table S1](#sup1){ref-type="supplementary-material"} for cell genotypes). Bar graphs show densitometrically quantified band intensity values (*n*=3 or more) normalized to actin (loading control, LC). Asterisks show differences vs cell line with highest SMO expression. (**e**, **f**) Methylation levels in the proximal *SMO* regulatory region in (**e**) untreated LAC CSC lines and (**f**) commercial LAC cell lines before and after 5-AZA treatment. Cell lines are classified as SMO^high^ (SMO^H^) or SMO^low^ (SMO^L^) based on findings shown in panels **c** and **d**. (**g**, **h**) Effect of 5-AZA-mediated demethylation on *SMO* expression (mRNA and protein) in (**g**) commercial LAC cell lines and (**h**) patient-derived LAC CSC lines. The mRNA level in each treated sample was calibrated against the corresponding basal level. LC: GAPDH. Bar graphs: densitometric analyses. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001](onc201791f1){#fig1}

![GLI1 inhibition diminishes proliferation and stemness in LAC cells. (**a**--**d**) LAC cells viability is diminished by GLI1 knockdown in (**a**) commercial cell lines (siRNA-mediated) and (**b**) patient-derived CSCs (shRNA-mediated); similar reductions are seen in (**c**) cell lines and (**d**) CSCs treated for 48 h with the GLI1 antagonist GANT61 or DMSO (−). Bar graphs show viability (MTS assay); immunoblots show endogenous GLI1 protein levels. LC: GAPDH. Numbers below blots indicate densitometrically quantified protein expression. (**e**) Effects of GANT61 on oncosphere formation in LAC CSC lines before and after transduction with shGLI1. Bar graphs: frequencies of oncosphere-forming cells (OFC, % of seeded cells that formed oncospheres) under indicated experimental conditions are normalized to the frequency observed in shSCRAMBLE-infected cells treated with DMSO alone (controls, CTRL, expressed as 100%). Photomicrographs: Representative images of oncospheres observed in DMSO-treated CSCs infected with shGLI1 or shSCRAMBLE (CTRL). Scale bar: 50 μm. (**f**) Percentage of CSCs exhibiting high ALDH activity (ALDH^+^ cells) after GANT61 or CTRL treatment (AldeFluor assay). (**g**) Expression (mRNA and protein) of stem cell markers OCT4 and ABCG2 in GANT61- and CTRL-treated (dashed line) CSCs. LC: GAPDH. \**P*\< 0.05. ALDH, aldehyde dehydrogenase.](onc201791f2){#fig2}

![GLI1 inhibition produces antitumor effects in LAC CSC-derived XTs. (**a**) Up: growth of XTs generated in mice by s.c. flank injections of LAC CSC-2 (XT-2), CSC-3 (XT-3) and CSC-4 (XT-4). Results are shown for 4 weeks of treatment with i.p. GANT61 or vehicle (CTRL). Bottom: representative image of XTs after vehicle treatment of mice or after GANT61 treatment. Scale bar: 1 cm. (**b**) Human *GLI1* and *PTCH1* mRNA levels in XTs from GANT61-treated and CTRL (dashed line) mice. (**c**) GANT61's effects on endogenous GLI1, ABCG2 and OCT4 protein expression in XTs. Bar graphs: densitometric analyses (see [Supplementary Figure S3b](#sup1){ref-type="supplementary-material"} for OCT4 IHC). (**d**, **e**) XT sections from GANT61-treated and CTRL mice were (**d**) immunostained for the proliferation marker KI-67 and (**e**) subjected to TUNEL assay for apoptosis. Representative results are shown (magnification: × 20; scale bar: 50 μm) with percentages of labeled cells (bar graphs on the right). Results are means±s.d. (*n*= 3). \**P*\<0.05, \*\**P*\<0.01 versus CTRLs.](onc201791f3){#fig3}

![MEK/ERK1/2 pathway regulates GLI1 phosphorylation. (**a**, **b**) Western blot analysis of endogenous levels of GLI1, phosphorylated ERK1/2 (p-ERK1/2) and actin (LC) in commercial LAC cell lines (H1734, H1437) and CSCs 2, 3, 4 after 48 h U0126 treatments. Bar graphs: densitometric analyses. Dashed line: CTRL treatment. \**P*\<0.05; \*\**P*\<0.01. (**c**) A549 and CSC-2 treated with U0126 for 4 h were lysed and subjected to (left) IP---western blot assay to assess endogenous levels of phosphorylated GLI1 (p-GLI1). Right: WB analysis of input of samples subjected to IP. (**d**) Immunofluorescence assay of endogenous GLI1 expression in A549 after 12 h of U0126 treatment. Nuclei are counterstained with Hoechst. Scale bars: 10 μm. (**e**) *In vitro* kinase assay. Recombinant GST-GLI1N (fragment 2-234) or GST were incubated with or without recombinant ERK1 for 20 min. Phosphorylation was revealed by PAN anti-pSer immunoblot. Total levels of GST and GST-GLI1N, revealed by α-GST immunoblot, are shown.](onc201791f4){#fig4}

![Noncanonical activation of GLI1 in LAC cells. (**a**, **b**) Western blots of endogenous protein levels of NRP2, GLI1 and P-ERK1/2 and actin (LC) in commercial LAC cell lines (H1734, H1437) and CSCs 2, 3, 4 after siRNA-mediated (**a**) or short-hairpin-mediated (**b**) silencing of NRP2. Bar graphs: densitometric analyses. Dashed line: CTRL treatment. (**c**--**f**) Cell viability (MTS assay) in (**c**) LAC cell lines after siRNA silencing of NRP2, GLI1 and both; in (**d**) CSCs after short-hairpin mediated silencing of NRP2, GLI1 and both; and in (**e**) in LAC cell lines and (**f**) LAC CSCs treated for 48 h with GANT61, U0126 or both. \**P*\<0.05, \*\**P*\<0.01 vs sham-treated/sham-transfected controls.](onc201791f5){#fig5}

![Autocrine GLI1 activation and paracrine HH--GLI signaling in LAC. (**a**, **b**) Cancer-cell component of XTs: basal mRNA levels of (**a**) human *NRP2* and (**b**) *VEGFA* vs levels in commercial normal human lung tissue (NL). Panel (a) shows IHC analysis of NRP2 expression in XT-3. Magnification: × 20, scale bar: 50 μm. (**c**) Human *SHH* mRNA levels in the cancer-cell component of XTs 2, 3 and 4 and normal human lung tissue (NL). (**d**) Representative IHC images of SHH and human nuclei (HuNu) staining in paraffin-embedded section of XT-3. Magnification: × 20, scale bar: 50 μm. (**e**) Relative expression of *Gli1* and *VegfA* mRNA in normal murine lung fibroblasts (LF) treated for 24 h with recombinant murine Shh or BSA alone (CTRL). Results are reported as means±s.d. (*n*=4). (**f**, **g**) Stromal component of XTs 2--4 samples from GANT61-treated and CTRL mice: mRNA levels of murine (**f**) Gli1 and (**g**) VegfA. Gli1 levels are expressed vs normal murine LFs. Values in **a**--**d** and **f**--**g** are means±s.d. from four or more tumors. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\>0.001.](onc201791f6){#fig6}

![Noncanonical GLI1 signaling sustaining LAC growth and CSC maintenance. The HH pathway effector GLI1 can be activated even in the absence of SMO, the canonical upstream activator of HH signaling, whose expression is epigenetically silenced in many GLI1-expressing LACs. GLI1 serves as a downstream effector of oncogenic MAPK/ERK signaling, which can be triggered by ligand-binding events at NRP2 receptors expressed by the cancer cells. GLI1 then promotes features involved in tumor growth and CSC maintenance, including the transcription of known HH target genes (for example, *ABCG2* and *VEGFA*). The VEGFA that binds epithelial-cell NRP2 receptors is secreted by the epithelial cells themselves, and this autocrine signaling loop is self-amplified by GLI1-upregulated transcription of both the receptor (NRP2) and its ligand (VEGFA). NRP2/ERK/GLI signaling can also be activated in a paracrine fashion by VEGFA secreted by cells in the tumor stroma. The stromal VEGFA production is the result of *canonical* SMO-dependent HH--GLI signaling triggered by SHH secreted by epithelial cells. The output of this stromal signaling includes VEGFA, which in turn bind tumor-cell NRP2, thereby triggering the *noncanonical* MAPK/ERK-mediated GLI1 activation illustrated in the upper panel.](onc201791f7){#fig7}
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